Tag: #glp1

FDA proposes excluding semaglutide, tirzepatide and liraglutide from 503B bulks list

FDA proposes removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, potentially limiting outsourcing facilities' ability to compound GLP‑1 drugs.

#fda, #glp1, #compounding, #semaglutide, #tirzepatide

23andMe study finds common gene variants modestly affect weight loss and nausea on GLP‑1 drugs

A Nature paper by 23andMe links common DNA variants to small differences in weight loss and nausea on GLP‑1 drugs; the company released a consumer report.

#genetics, #glp1, #23andme, #weightloss, #semaglutide

Tirzepatide shows broader heart-and-kidney edge over dulaglutide in diabetes trial analysis

A post hoc look at the 13,000-patient SURPASS-CVOT trial finds fewer combined heart and kidney events with tirzepatide than dulaglutide.

#diabetes, #cardiology, #glp1, #kidneydisease, #clinicaltrials

Lilly’s daily GLP-1 pill beats Novo’s oral semaglutide in diabetes trial, but side effects drive more dropouts

A Phase 3 head-to-head study finds Lilly’s orforglipron lowered A1c and weight more than Rybelsus, with higher quit rates.

#diabetes, #glp1, #weightloss, #pharma, #clinicaltrials